MGC Pharma PLC (LON:MXC, ASX:MXC) Co-founder and Managing director, Roby Zomer joins Proactive London's Katie Pilbeam to discuss the details of the landmark deal signed with an American drug distributor worth a minimum US$24mln over the next three years.
The tie-up with AMC Holdings will see MGC supplying the phytomedicine products CannEpil, CogniCann and CimetrA for use in clinical trials.
An initial order for US$3mln will be placed five days after a national clinical trial number has been granted. The additional US$21mln will come in years two and three.